pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,854 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT811Endpoints611BioPharma Dive235onclive165Fierce Biotech79BioSpace78raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • Supreme Court sides with Hikma in 'skinny label' case
    The Supreme Court unanimously sided with Hikma Pharmaceuticals and its “skinny label” version of a prescription-strength fish oil pill in a case that was closely watched by the generics industry. T…
    Endpoints · 1mo ago↗ source
  • Novo Holdings backs European fund; Alnylam sends second obesity drug into clinic
    Plus news about IMU Biosciences, Autobahn and Jade Biosciences. 💸 Novo Holdings invests in Europe-focused fund: The investment manager of the Novo Nordisk Foundation's fortunes is backing the Scal…
    Endpoints · 1mo ago↗ source
  • Alnylam, Inceptive ink AI deal potentially worth $2B
    The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.
← prev
page 39 of 75
next →
21
fda recalls20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
BioPharma Dive · 1mo ago
↗ source
  • STAT+: AI titans push Congress for DNA safeguards
    Inceptive Nucleics and Alnylam's partnership, why Grail's "failed" trial still matters, and other biotech news from The Readout
    STAT · 1mo ago↗ source
  • STAT+: Utah Medical Board scolded for going rogue with AI criticism
    In this edition of STAT Health Tech: An update on the Utah pilot that uses a chatbot to renew drug prescriptions, AI scribes for patients, and more.
    STAT · 1mo ago↗ source
  • An ADC specialist sinks on safety concerns for blood cancer drug
    Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”
    BioPharma Dive · 1mo ago↗ source
  • Otsuka showcases kidney drug data; Pfizer cuts an AI deal
    Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off gen…
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and more
    Eli Lilly is halving its originally planned investment in the production of weight loss syringes in Germany in response to a cost-cutting law
    STAT · 1mo ago↗ source
  • Parabilis Medicines charts $413M IPO to back peptide pipeline
    Parabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut. If the drug developer follows through with it…
    Endpoints · 1mo ago↗ source
  • Scientists uncover a new hiding spot for HIV
    An Ebola update, Trump to strip job protections of NIH officials, and more health news from Morning Rounds
    STAT · 1mo ago↗ source
  • ADC Therapeutics' confirmatory data for Zynlonta muddied by death rates
    ADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial. The company said ...
    Endpoints · 1mo ago↗ source
  • STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?
    Revolution Medicines' pancreatic cancer drug has not yet been approved — and already talk has shifted to how (and when) its use might be expanded.
    STAT · 1mo ago↗ source
  • Male puberty is understudied — but when it starts may predict long-term health risks
    Due to a significant gender gap, far less is known about the health risks of early or late puberty onset among boys than girls.
    STAT · 1mo ago↗ source
  • What happens at a longevity festival?
    What happens at a longevity festival? On this week's STATus Report, Alex Hogan gets a dispatch from STAT's Sarah Todd.
    STAT · 1mo ago↗ source
  • Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this story
    An oncologist shares three lessons from the world’s first randomized trial on a multi-cancer early detection.
    STAT · 1mo ago↗ source
  • Opinion: Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwise
    “One of the cancer community’s worst fears is coming to pass,” writes Gwen Nichols of Blood Cancer United.
    STAT · 1mo ago↗ source
  • STAT+: After hospitals, patients get a turn to bring AI into the doctor’s office
    Ambient scribes were the first large-scale application of AI in health care. Now developers are pitching them as diligent note-takers for patients.
    STAT · 1mo ago↗ source
  • ADC biotech Ona Therapeutics secures $86.6M in Series B raise
    Barcelona-based Ona Therapeutics has raised $86.6 million in a Series B round to advance two ADC candidates into the clinic. CEO Valerie Vanhooren told Endpoints News in an interview that the cash…
    Endpoints · 1mo ago↗ source
  • A Spanish biotech banks $87M to make differentiated ADCs
    Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.
    BioPharma Dive · 1mo ago↗ source
  • STAT+: Trump administration to strip job protections of top NIH officials, grants staff
    Among the affected positions, which the White House estimates to be 8,000, are high-level officials who oversee research grants from the NIH.
    STAT · 1mo ago↗ source
  • Alnylam to pay $30M upfront to AI startup Inceptive in RNA R&D deal
    Alnylam Pharmaceuticals announced its first discovery-focused AI deal Wednesday, tapping a Silicon Valley biotech startup to see if AI can boost its R&D efforts. Alnylam and Inceptive signed a coll…
    Endpoints · 1mo ago↗ source
  • STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeutics
    Alnylam announced a three-year deal with Inceptive, worth up to $2 billion, with $30 million up front in cash and equity in the startup.
    STAT · 1mo ago↗ source
  • STAT+: HaloMD faces lawsuit alleging No Surprises Act middleman used ‘sham letter,’ misleading data
    Highmark Health is the fourth insurer to sue HaloMD, seeking to overturn arbitration wins.
    STAT · 1mo ago↗ source
  • Bristol Myers turns focus to AI costs after broad rollout to workers
    PALO ALTO, CA — After giving artificial intelligence tools to thousands of employees, Bristol Myers Squibb is now working to get a handle on the costs of the technology and where it’s actually crea…
    Endpoints · 1mo ago↗ source
  • Axsome pushes back generic entry for narcolepsy drug until 2040
    Axsome Therapeutics has successfully delayed generic competition for its narcolepsy drug Sunosi until 2040. The company announced on Wednesday that it has reached a settlement with the last applica…
    Endpoints · 1mo ago↗ source